VOLUNTARY ANNOUNCEMENT

“VORTIOXETINE HYDROBROMIDE TABLETS” OBTAINS DRUG REGISTRATION CERTIFICATE

The board of directors (the “Board”) of Sino Biopharmaceutical Limited (the “Company”, together with its subsidiaries, the “Group”) announces that “Vortioxetine Hydrobromide Tablets” (Brand name: Qingshuxin (晴舒欣)), an antidepressant developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China. The product was filed as a Chemicals Category 4 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has obtained approval for drug registration in China. The approved indication is: for the treatment of depression in adults.

Vortioxetine is a new type of antidepressant with multi-target mechanism of actions that combine 5-HT transporter (SERT) inhibition, 5-hydroxytryptamine (5-HT1A) receptor agonism and 5-HT3 receptor antagonism. Compared to traditional antidepressants (e.g., heterocyclic and tricyclic antidepressants), vortioxetine is similar in efficacy, but with fewer side effects as well as higher safety and tolerability, and therefore has become a commonly used first-line antidepressant in Europe and the United States.
In 2017, the World Health Organization (WHO) pointed out that the greatest illness faced by mankind in the 21st century is mental illness, of which depression requires special attention. In 2019, The Lancet Neurology, a medical journal, reported that there were approximately 95 million patients with depression in China according to prevalence data of the Chinese Mental Health Survey. At present, no generic version of vortioxetine hydrobromide tablet is available in China, and the Group is the first enterprise in the PRC to obtain the approval, breaking the monopoly of the branded drug and providing more treatment options for depression patients in China.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 July 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.